Drug companies’ marketing departments and legal departments negotiate among themselves to arrive at the desired level of label warnings to propose to the FDA.
When a drug company doesn’t move to strengthen the warning, it’s not because they can’t (as Wyeth claims in the lawsuit); rather, it’s because the marketing people within the company don’t want to.
Market Data 
Markets 
AI
